Adage Capital Partners Gp, L.L.C. Dyne Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,950,000 shares of DYN stock, worth $26.9 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,950,000
Previous 2,402,972
18.85%
Holding current value
$26.9 Million
Previous $86.3 Million
46.77%
% of portfolio
0.08%
Previous 0.16%
Shares
13 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$111 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$102 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$102 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$92.4 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$88 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $714M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...